Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM
JAMA 2006;295(3):293-298.
Review by M. Aldouri
Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study.
Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS
Br J Anaesth 2005;95(5):596-602.
Review by M. Aldouri
Recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.
Manning BJ, Hynes N, Courtney DF, Sultan S
Eur J Vasc Endovasc Surg 2005 Aug 12; [Epub ahead of print].
Review by M. Aldouri
Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.
The etiology of severe hemorrhage associated with trauma includes coagulopathy, hypothermia, acidosis, as well as platelet dysfunction, in addition to the direct effect of trauma... Read More
Off-label use of recombinant factor VIIA concentrates after cardiac surgery.
Despotis G, Avidan M, Lublin DM, et al.
Ann Thorac Surg 2005;80(1):3-5.
Review by M. Aldouri
Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
Raivio P, Suojaranta-Ylinen R, Kuitunen AH
Ann Thorac Surg 2005;80(1):66-71.
Review by M. Aldouri
Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial.
Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM
Br J Anaesth 2005;94(5):586-591.
Review by M. Aldouri
Is recombinant FVIIa the magic bullet in the treatment of major bleeding? [Editorial]
Spahn DR, Tucci MA, Makris M
Br J Anaesth 2005;94(5):553-555.
Review by M. Aldouri
First military use of activated Factor VII in an APC-III pelvic fracture.
Williams DJ, Thomas GO, Pambakian S, Parker PJ
Injury 2005;36(3):395-399.
Review by M. Aldouri
Recombinant activated factor VII for acute intracerebral hemorrhage.
Mayer SA, Brun NC, Begtrup K, et al.
N Engl J Med 2005;352(8):777-785.
Review by
Stopping the bleeding in intracerebral hemorrhage. [Editorial]
Brown DL, Morgenstern LB
N Engl J Med 2005;352(8):828-830.
Review by M. Aldouri
The use of recombinant factor VIIa in a patient with essential thrombocythaemia with uncontrolled surgical bleeding.
Cervera JS, Mena-Duran AV, Piqueras CS
Thromb Haemost 2005;93(2):383-384.
Review by M. Aldouri
Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage.
Busani S, Marietta M, Pasetto A, Girardis M
Thromb Haemost 2005;93(2):381-382.
Review by M. Aldouri
Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial.
Lodge JP, Jonas S, Oussoultzoglou E, et al.
Anesthesiology 2005;102(2):269-275.
Review by M. Aldouri
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
Aledort LM
J Thromb Haemost 2004;2(10):1700-1708.
Review by
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659